Evidence map›Paper›PMID 42370179›Full record

ArticleTheranostics2026

A clinically translatable, irreversibly attenuated

Dinh-Huy Nguyen, Sung-Hwan You, Khuynh Van Nguyen, Phuong Thi-Minh Nguyen, Hien Thi-Thu Ngo, Khang Vuong Tran, Thanh Quang Tran, Miryoung Song, Yeongjin Hong, Jung-Joon Min

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dinh-Huy NguyenInstitute for Molecular Imaging and Theranostics, Chonnam National University, Hwasun, Jeonnam 61469, Republic of Korea.
Sung-Hwan YouCNCure Co., Ltd., Hwasun, Jeonnam 58128, Republic of Korea.
Khuynh Van NguyenInstitute for Molecular Imaging and Theranostics, Chonnam National University, Hwasun, Jeonnam 61469, Republic of Korea.
Phuong Thi-Minh NguyenInstitute for Molecular Imaging and Theranostics, Chonnam National University, Hwasun, Jeonnam 61469, Republic of Korea.
Hien Thi-Thu NgoInstitute for Molecular Imaging and Theranostics, Chonnam National University, Hwasun, Jeonnam 61469, Republic of Korea.
Khang Vuong TranInstitute for Molecular Imaging and Theranostics, Chonnam National University, Hwasun, Jeonnam 61469, Republic of Korea.
Thanh Quang TranDepartment of Microbiology and Immunology, Chonnam National University Medical School, Gwangju 61469, Republic of Korea.
Miryoung SongDepartment of Bioscience and Biotechnology, Hankuk University of Foreign Studies, Yongin, Republic of Korea.
Yeongjin HongInstitute for Molecular Imaging and Theranostics, Chonnam National University, Hwasun, Jeonnam 61469, Republic of Korea.
Jung-Joon MinInstitute for Molecular Imaging and Theranostics, Chonnam National University, Hwasun, Jeonnam 61469, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale: The immunosuppressive tumor microenvironment (TME) remains a major barrier to the efficacy of immune checkpoint blockade (ICB) therapy, underscoring the need for strategies that can safely reprogram the TME to enhance cancer immunity. Methods: Here, we developed CNC018, a clinically translatable Results: CNC018 exhibited markedly reduced intracellular invasiveness, was rapidly cleared from non-tumor tissues, and displayed a 2.2-fold higher median lethal dose compared with Conclusions: CNC018 represents a promising next-generation bacterial adjuvant with strong translational potential to safely enhance ICB efficacy in clinical cancer therapy.

Indexed as

Adjuvants, ImmunologicImmune Checkpoint InhibitorsImmunotherapyNeoplasmsSalmonella typhimuriumAnimalsBacterial ProteinsCD8-Positive T-LymphocytesCell Line, TumorFemaleGenomic IslandsHumansMembrane ProteinsMiceTumor MicroenvironmentAdjuvants, ImmunologicBacterial ProteinsImmune Checkpoint InhibitorsMembrane ProteinsSpi1 protein, SalmonellaSPI-2 protein, Salmonellabacterial immunotherapyDAMPs (damage-associated molecular patterns)immune checkpoint blockade (ICB)Salmonella typhimuriumsingle-cell RNA sequencingtumor microenvironment reprogramming

Identifiers

PMID42370179
PMCPMC13294988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.